FutureBridge set to engage with industry leaders at 2024 ASCO® Annual Meeting and BIO 2024 International Conference

"At these conferences, we look forward to sharing our expertise on the future of medicines, healthcare solutions, disruptive trends, emerging technologies, and therapeutic platforms," said Shivali Jasrotia, Senior Consultant at FutureBridge. "We aim to strengthen relationships with existing clients and establish new collaborations with industry, academia, patient advocates, innovators, and key opinion leaders." "At these conferences, we look forward to sharing our expertise on the future of...

UTRECHT, Netherlands, 31/05/2024 (informazione.news - comunicati stampa - salute e benessere)

ASCO 2024, with over 40,000 members, will showcase breakthroughs in oncology, including advancements in immune checkpoint blockade optimization, lung cancer treatment, breast cancer diagnostics, early melanoma intervention, and early-stage rectal cancer management. Major pharmaceutical companies will present outcomes and updates of their clinical programs, reflecting the diverse and dynamic progress in oncology.

The BIO International Conference is the premier biotech networking event, attracting over 20,000 industry leaders. This year's participants include leading biopharmaceutical companies such as Amgen, Pfizer, Novartis, Merck, and Gilead Sciences. The event facilitates the discovery of new opportunities and the development of partnerships within the biotech and pharmaceutical sectors.

Meet us at ASCO 2024 and BIO 2024 by scheduling a meeting here or you can write to shivali.jasrotia@futurebridge.com to learn how our evidence-based consulting solutions can drive results for pharma leaders and address their most critical business challenges.

:

FutureBridge is a techno-commercial consulting and advisory company. We track and advise the Top 200 clients of the Fortune 500 on the future of industries from a 1-to-25-year perspective. The company offers solutions through its hyper-personalised advisory services and intelligence platforms, The company's advisory unit leverages proprietary frameworks such as Hopper – Opportunity, Prioritization & Evaluation (HOPE), Weak Signal Management (WSM), and Scientific & Market Sentiment (SMS) that can identify weak and strong signals to become a trend in the future.

www.futurebridge.com | LinkedIn | Twitter

Video: https://mma.prnewswire.com/media/2426513/futurebridge_at_asco.mp4

 

View original content:https://www.prnewswire.co.uk/news-releases/futurebridge-set-to-engage-with-industry-leaders-at-2024-asco-annual-meeting-and-bio-2024-international-conference-302160339.html